Cancer research policies: the elderly, invisible patients?
Tijou-Traoré, Annick
Cancer research policies: the elderly, invisible patients? - 2022.
26
Although the government wishes to promote the development of therapeutic innovation and its access to all patients in the field of cancer, the fact remains that the elderly are still little beneficiaries. These patients are under-represented in clinical trials. Yet, we know that they represent the population most vulnerable to the occurrence of cancer. This paradoxical situation raises the question of health inequalities by age. This article proposes to question this medical problem and to highlight the logic behind its existence, from the point of view of 12 institutional and associative actors. The way they think about access to care and medical research is part of the complexity of defining and designating the elderly population. The causes they attribute to it are based on social, political and medical dimensions. The causes they attribute to it are based on social, political and medical dimensions, and reflect the interplay between the representation of the elderly, the inertia of public policies and pharmaceutical laboratories, and the lack of therapeutic activism by and/or for the elderly.
Cancer research policies: the elderly, invisible patients? - 2022.
26
Although the government wishes to promote the development of therapeutic innovation and its access to all patients in the field of cancer, the fact remains that the elderly are still little beneficiaries. These patients are under-represented in clinical trials. Yet, we know that they represent the population most vulnerable to the occurrence of cancer. This paradoxical situation raises the question of health inequalities by age. This article proposes to question this medical problem and to highlight the logic behind its existence, from the point of view of 12 institutional and associative actors. The way they think about access to care and medical research is part of the complexity of defining and designating the elderly population. The causes they attribute to it are based on social, political and medical dimensions. The causes they attribute to it are based on social, political and medical dimensions, and reflect the interplay between the representation of the elderly, the inertia of public policies and pharmaceutical laboratories, and the lack of therapeutic activism by and/or for the elderly.
Réseaux sociaux